Bill > HB4203

This bill amends the Illinois Insurance Code to expand coverage for ovarian cancer screenings by adding a new criterion for being "at risk for ovarian cancer" and broadening the definition of "surveillance tests for ovarian cancer". Specifically, the bill now includes individuals with a high level of CA-125 (a protein biomarker) as detected by a blood test screening as being considered at risk for ovarian cancer. Additionally, the bill expands the definition of ovarian cancer surveillance tests to include a wider range of medical imaging and diagnostic techniques, such as ultrasounds, MRIs, x-rays, CT scans, and CA-125 blood test screenings, replacing the previous more limited definition that only specified annual screenings using CA-125 testing, transvaginal ultrasound, and pelvic examination. The changes will apply to group health insurance policies that provide coverage for hospital or medical treatment, and the bill is set to take effect on January 1, 2028. This modification aims to provide more comprehensive and flexible screening options for individuals at risk of ovarian cancer, potentially enabling earlier detection and diagnosis.

https://www.ilga.gov/Legislation/BillStatus?DocNum=4203&GAID=18&DocTypeID=HB&SessionID=114&GA=104